强生公司近日宣布,单抗药物Stelara(ustekinumab)获FDA批准,单独用药或与甲氨蝶呤联合用药,用于18岁及以上活动性银屑病关节炎患者的治疗。获批的治疗方法为:0周和4周注射45 mg Stelara,随后每12周注射1次。此外,Stelara也于近日获得了欧盟委员会的批准,单独用药或与甲氨蝶呤联合用药,用于对非生物疾 Johnson & Johnson recently announced that the monoclonal antibody, Stelara (ustekinumab), was approved by the FDA for its use alone or in combination with methotrexate for the treatment of active psoriatic arthritis patients 18 years of age and older. Approved treatments were: 45 mg Stelara at weeks 0 and 4 and then 1 every 12 weeks. In addition, Stelara also recently obtained the approval of the European Commission, alone or in combination with methotrexate for non-biological disease